Study of the Inappropriate Secretion of FGF23 in Patients Followed in Hospital in a Context of Hypophosphatemia (IFEH)

University Hospital, Clermont-Ferrand

Status: Completed

Conditions: Unexplained Hypophosphatemia; Hypophosphatemia Without Immediate Anteriority

Treatments: Behavioral: unexplained hypophoshatemia

Study type: Observational

Funder types: Other

Identifiers

NCT04846647

RNI 2021 BOUVIER

2021-A00284-37 (Other Identifier)

Details and patient eligibility

About

The discovery of FGF23, the missing link in the long researched and finally found phosphate metabolism, marked a turning point in the understanding and physiopathology of specific hypophosphatemia. By inhibiting the renal reabsorption of phosphate and the production of calcitriol, FGF23 behaves like a hypophosphatemia hormone.

Hypersecretion of FGF23 can occur in the case of genetic abnormalities (X-linked hypophosphatemic vitamin-resistant rickets, recessive or dominant hypophosphatemic rickets, McCune-Albright syndrome ...) or acquired abnormalities (oncogenic osteomalacia). Oncogenic osteomalacia can be induced by hyperproduction of FGF23 by benign tumours of mesenchymal origin. But more recently, several cases of malignant tumours secreting FGF23 have also been described (prostate, colon, breast, ovarian and lung cancers, pulmonary carcinoma, etc.)

Full description

To date, even if the incidence of FGF23-secreting tumours seems rare, no precise bibliographical data is available in the scientific literature. Future studies will have to address this issue in order not to underestimate the frequency of this complication.

In this context, investigators would like to study the incidence of inappropriate FGF23 increase from a collection of biological samples carried out on 500 patients treated at the Clermont-Ferrand University Hospital for hypophosphatemia.

Enrollment: 260 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Major patient, male or female
• Taken care of at the Clermont-Ferrand University Hospital or the Jean Perrin Centre
• In a context of hypophosphatemia (< 0.80 mmol/L), without immediate anteriority and not occurring during hospitalisation
• In capacity to express informed consent to participate in research
• Affiliated to a social security system

Exclusion criteria

• Previously diagnosed hypophosphatemia
• Hypophosphatemia during hospitalisation
• Haemodialysis patient
• Refusal to participate

Trial design

260 participants in 1 patient group

Unexplained hypophosphatemia

Description:

Collection of additional blood volume (approximately 10 mL) during blood tests provided as part of the usual medical care.

Treatment:

Behavioral: unexplained hypophoshatemia